Futura Medical plc (AIM:FUM)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 4.36M -84.6% |
| Revenue (ttm) | 7.93M -5.6% |
| Net Income | -6.29M |
| EPS | -0.02 |
| Shares Out | 581.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,968,207 |
| Average Volume | 8,484,697 |
| Open | 0.6900 |
| Previous Close | 0.7500 |
| Day's Range | 0.6500 - 0.7500 |
| 52-Week Range | 0.6000 - 15.0000 |
| Beta | 0.01 |
| RSI | 29.08 |
| Earnings Date | Apr 29, 2026 |
About Futura Medical
Futura Medical plc research, develops, and commercializes pharmaceutical and healthcare products for sexual health. The company’s lead product includes Eroxon, a topical gel for the treatment of erectile dysfunction. It also develops WSD4000 for the treatment of sexual dysfunction in women. The company operates in the United Kingdom, the European Union, the United States, and internationally. Futura Medical plc was incorporated in 2001 and is headquartered in Guildford, the United Kingdom. [Read more]
Financial Performance
Financial StatementsNews
Futura Medical PLC (FAMDF) Full Year 2025 Earnings Call Highlights: Strategic Shifts and ...
Futura Medical PLC (FAMDF) Full Year 2025 Earnings Call Highlights: Strategic Shifts and Product Innovations Amid Financial Challenges
Full Year 2025 Futura Medical PLC Earnings Call Transcript
Full Year 2025 Futura Medical PLC Earnings Call Transcript
AIM Market Roundup: Acuity RM, TAP Global, ADM Energy
Acuity RM, TAP Global, ADM Energy are today's top risers, while Futura Medical, Spaceandpeople take the biggest fall on London's AIM market
Futura Medical Earnings Call Transcript: H2 2025
2025 saw a strategic reset with sharply lower revenues, cost base alignment, and a focus on disciplined cash management. Eroxon Intense and WSD4000 development advanced, with launches targeted for 2027 and 2028, and APAC expansion prioritized.
Futura Medical Earnings Call Transcript: H1 2025
H1 2025 saw disappointing repeat sales and revenue, leading to a significant downgrade in full-year expectations and a strategic review. Cash runway extends into January 2026, with new product launches and financing options under active consideration.
Futura Medical Earnings Call Transcript: H2 2024
Achieved first profit in 2024 with GBP 14 million revenue and 70% gross margin, driven by Eroxon launches in 15+ countries. Pipeline products advancing, but sales guidance revised lower due to early-stage market dynamics and product effectiveness in younger men.
Futura Medical Earnings Call Transcript: H1 2024
Reported first-ever profit and over 300% revenue growth in H1 2024, driven by Eroxon’s rollout in 10+ countries and upcoming U.S. launch with Haleon. Gross margin was 44%, with significant manufacturing investments and updated guidance expected.